CG Oncology (CGON) Stock Overview
A late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
CGON Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CG Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.70 |
| 52 Week High | US$40.47 |
| 52 Week Low | US$14.80 |
| Beta | 0 |
| 1 Month Change | -3.93% |
| 3 Month Change | 3.38% |
| 1 Year Change | -24.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -30.86% |
Recent News & Updates
Recent updates
We're Not Very Worried About CG Oncology's (NASDAQ:CGON) Cash Burn Rate
Jul 16
A First Take On CG Oncology
Jan 10CG Oncology: Positive Phase 3 Outcome Could Lead To BLA Of Cretostimogene
Dec 13Companies Like CG Oncology (NASDAQ:CGON) Are In A Position To Invest In Growth
Oct 04CG Oncology: Promising Data, But Looks Expensive
Aug 26CG Oncology, Inc. (NASDAQ:CGON) Shares Could Be 42% Below Their Intrinsic Value Estimate
Jul 25CG Oncology Bringing Undervalued Innovation To Bladder Cancer
Jul 09CG Oncology: ASCO Play And Top-Line Data End Of 2024 Could Drive Further Value
May 06Shareholder Returns
| CGON | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.4% | 4.5% | 1.0% |
| 1Y | -24.9% | -5.3% | 17.0% |
Return vs Industry: CGON underperformed the US Biotechs industry which returned -5.3% over the past year.
Return vs Market: CGON underperformed the US Market which returned 17% over the past year.
Price Volatility
| CGON volatility | |
|---|---|
| CGON Average Weekly Movement | 6.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CGON has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CGON's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 113 | Arthur Kuan | cgoncology.com |
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003, which is in phase 3 clinical trial for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 that is in phase 2 clinical trial to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy that is in phase 3 clinical trial for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008, which is in phase 2 clinical trial for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients.
CG Oncology, Inc. Fundamentals Summary
| CGON fundamental statistics | |
|---|---|
| Market cap | US$1.96b |
| Earnings (TTM) | -US$128.08m |
| Revenue (TTM) | US$551.00k |
Is CGON overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CGON income statement (TTM) | |
|---|---|
| Revenue | US$551.00k |
| Cost of Revenue | US$84.74m |
| Gross Profit | -US$84.18m |
| Other Expenses | US$43.90m |
| Earnings | -US$128.08m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.68 |
| Gross Margin | -15,278.40% |
| Net Profit Margin | -23,245.19% |
| Debt/Equity Ratio | 0% |
How did CGON perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/17 19:21 |
| End of Day Share Price | 2025/08/15 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CG Oncology, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Chen Yang | BofA Global Research |
| Joshua Schimmer | Cantor Fitzgerald & Co. |